Novel coronavirus vaccine polypeptide and application of nanoemulsion preparation of novel coronavirus vaccine polypeptide in prevention of infection of novel coronavirus strain and mutant strain
The invention discloses a coronavirus SARS-CoV-2 vaccine polypeptide, a polypeptide composition and application of a nanoemulsion preparation of the polypeptide composition in prevention of infection of a coronavirus SARS-CoV-2 wild strain and a mutant strain. Specifically, the invention provides a coronavirus SARS-CoV-2 vaccine polypeptide with an amino acid sequence derived from S protein of an SARS-CoV-2 wild strain and a mutant strain, and the vaccine polypeptide provided by the invention can enable an organism to generate a high-level and lasting humoral immune response aiming at the SARS-CoV-2, generate a high-titer RBD binding antibody and a neutralizing antibody for blocking the binding of RBD and ACE2. The vaccine polypeptide disclosed by the invention can be used for preventing infection of a variety of mutant strains such as SARS-CoV-2 wild strains, B.1. 1.7, B.1.351, B.1.617 and the like..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Europäisches Patentamt - (2022) vom: 02. Dez. Zur Gesamtaufnahme - year:2022 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
GONG LIKUN [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-12-02, Last update posted on www.tib.eu: 2023-06-27, Last updated: 2023-06-30 |
---|
Patentnummer: |
CN115417917 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA016775260 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA016775260 | ||
003 | DE-627 | ||
005 | 20230630123856.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230607s2022 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA016775260 | ||
035 | |a (EPA)CN115417917 | ||
035 | |a (EPA)84230446 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a GONG LIKUN |e verfasserin |4 aut | |
245 | 1 | 0 | |a Novel coronavirus vaccine polypeptide and application of nanoemulsion preparation of novel coronavirus vaccine polypeptide in prevention of infection of novel coronavirus strain and mutant strain |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2022-12-02, Last update posted on www.tib.eu: 2023-06-27, Last updated: 2023-06-30 | ||
520 | |a The invention discloses a coronavirus SARS-CoV-2 vaccine polypeptide, a polypeptide composition and application of a nanoemulsion preparation of the polypeptide composition in prevention of infection of a coronavirus SARS-CoV-2 wild strain and a mutant strain. Specifically, the invention provides a coronavirus SARS-CoV-2 vaccine polypeptide with an amino acid sequence derived from S protein of an SARS-CoV-2 wild strain and a mutant strain, and the vaccine polypeptide provided by the invention can enable an organism to generate a high-level and lasting humoral immune response aiming at the SARS-CoV-2, generate a high-titer RBD binding antibody and a neutralizing antibody for blocking the binding of RBD and ACE2. The vaccine polypeptide disclosed by the invention can be used for preventing infection of a variety of mutant strains such as SARS-CoV-2 wild strains, B.1. 1.7, B.1.351, B.1.617 and the like. | ||
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a che | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
650 | 4 | |a 615 | |
700 | 0 | |a REN JIN |4 aut | |
700 | 0 | |a HUANG WEI |4 aut | |
700 | 0 | |a GAN YONG |4 aut | |
700 | 0 | |a ZHENG YONGTANG |4 aut | |
700 | 0 | |a SUN JIANHUA |4 aut | |
700 | 0 | |a ZHANG XINXIN |4 aut | |
700 | 0 | |a LONG YIRU |4 aut | |
700 | 0 | |a QIN QIUPING |4 aut | |
700 | 0 | |a LIU TINGTING |4 aut | |
700 | 0 | |a TANG FENG |4 aut | |
700 | 0 | |a YU PAN |4 aut | |
700 | 0 | |a MIAO YUNQIU |4 aut | |
700 | 0 | |a CAI YONGLONG |4 aut | |
700 | 0 | |a QIN MIAN |4 aut | |
700 | 0 | |a SONG TIANZHANG |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 02. Dez. |
773 | 1 | 8 | |g year:2022 |g day:02 |g month:12 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/84230446/publication/CN115417917A1?q=CN115417917 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
936 | u | w | |j 2022 |b 02 |c 12 |
951 | |a AR | ||
952 | |j 2022 |b 02 |c 12 |